日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial

Onvansertib 联合化疗和贝伐单抗用于 KRAS 突变转移性结直肠癌的二线治疗：一项单组 II 期试验

期刊:Journal of Clinical Oncology
影响因子:42.1
doi:10.1200/JCO-24-01266
Daniel H Ahn, Maya Ridinger, Timothy L Cannon, Lawrence Mendelsohn, Jason S Starr, Joleen M Hubbard, Anup Kasi, Afsaneh Barzi, Errin Samuëlsz, Anju Karki, Ramanand A Subramanian, Divora Yemane, Roy Kim, Chu-Chiao Wu, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz
肿瘤
肠癌
PECAM1
发表日期：2025
文献求助 收藏

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Onvansertib 联合 FOLFIRI 和贝伐单抗用于 KRAS 突变转移性结直肠癌二线治疗：Ib 期临床研究

期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-23-3053
Daniel H Ahn #, Afsaneh Barzi #, Maya Ridinger #, Errin Samuëlsz, Ramanand A Subramanian, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz
肿瘤
肠癌
发表日期：2024
文献求助 收藏

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer

AKT 抑制可增强前列腺癌患者对 Polo 样激酶 1 抑制剂 Onvansertib 的敏感性

期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-23-0933
Mannan Nouri, Andreas Varkaris, Maya Ridinger, Susan L Dalrymple, Christopher M Dennehy, John T Isaacs, David J Einstein, W Nathaniel Brennen, Steven P Balk
信号转导
肿瘤
前列腺癌
PI3K/Akt
发表日期：2024
文献求助 收藏

PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights

PLK1 抑制剂 Onvansertib 增强 Alpelisib 对对 Palbociclib 和内分泌疗法耐药的 PIK3CA 突变 HR 阳性乳腺癌的疗效：临床前见解

期刊:Cancers
影响因子:
doi:10.3390/cancers16193259
Sreeja Sreekumar, Elodie Montaudon, Davis Klein, Migdalia E Gonzalez, Pierre Painsec, Héloise Derrien, Laura Sourd, Tod Smeal, Elisabetta Marangoni, Maya Ridinger
肿瘤
乳腺癌
发表日期：2024
文献求助 收藏

Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

Plk1 抑制剂和阿比特龙协同破坏有丝分裂并杀死不同来源的癌细胞，而不依赖于雄激素受体信号传导

期刊:Cancer Research
影响因子:12.5
doi:10.1158/0008-5472.CAN-22-1533
Jesse C Patterson, Andreas Varkaris, Peter J P Croucher, Maya Ridinger, Susan Dalrymple, Mannan Nouri, Fang Xie, Shohreh Varmeh, Oliver Jonas, Matthew A Whitman, Sen Chen, Saleh Rashed, Lovemore Makusha, Jun Luo, John T Isaacs, Mark G Erlander, David J Einstein, Steven P Balk, Michael B Yaffe
信号转导
肿瘤
肿瘤细胞
发表日期：2023
文献求助 收藏

Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia

在PLK1抑制剂onvansertib联合地西他滨治疗复发或难治性急性髓系白血病的1b/2期研究中，剪接体突变与临床反应相关。

期刊:Annals of Hematology
影响因子:3
doi:10.1007/s00277-023-05442-9.
Peter J P Croucher,Maya Ridinger,Pamela S Becker,Tara L Lin,Sandra L Silberman,Eunice S Wang,Amer M Zeidan
白血病
肿瘤
PLK1
发表日期：2023
文献求助 收藏

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas

Onvansertib 与紫杉醇联合治疗铂类耐药卵巢癌

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.3
doi:10.1177/17588359221095064
Roberta Affatato, Michela Chiappa, Federica Guffanti, Francesca Ricci, Laura Formenti, Robert Fruscio, Marta Jaconi, Maya Ridinger, Mark Erlander, Giovanna Damia
肿瘤
卵巢癌
发表日期：2022
文献求助 收藏

Tuft Cells Inhibit Pancreatic Tumorigenesis in Mice by Producing Prostaglandin D2

丛状细胞通过产生前列腺素 D2 抑制小鼠胰腺肿瘤发生

期刊:Gastroenterology
影响因子:25.7
doi:10.1053/j.gastro.2020.07.037
Kathleen E DelGiorno, Chi-Yeh Chung, Vera Vavinskaya, H Carlo Maurer, Sammy Weiser Novak, Nikki K Lytle, Zhibo Ma, Rajshekhar R Giraddi, Dezhen Wang, Linjing Fang, Razia F Naeem, Leonardo R Andrade, Wahida H Ali, Hubert Tseng, Crystal Tsui, Vikas B Gubbala, Maya Ridinger-Saison, Makoto Ohmoto, Galin
肿瘤
肿瘤细胞
发表日期：2020
文献求助 收藏

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

新型口服 PLK1 抑制剂 Onvansertib 联合治疗复发或难治性急性髓系白血病患者的 Ib 期研究

期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-20-2586
Amer M Zeidan, Maya Ridinger, Tara L Lin, Pamela S Becker, Gary J Schiller, Prapti A Patel, Alexander I Spira, Michaela L Tsai, Errin Samuëlsz, Sandra L Silberman, Mark Erlander, Eunice S Wang
肿瘤
白血病
WB
发表日期：2020
文献求助 收藏

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

针对 LIF 介导的旁分泌相互作用进行胰腺癌治疗和监测

期刊:Nature
影响因子:50.5
doi:10.1038/s41586-019-1130-6
Yu Shi, Weina Gao #, Nikki K Lytle #, Peiwu Huang, Xiao Yuan, Amanda M Dann, Maya Ridinger-Saison, Kathleen E DelGiorno, Corina E Antal, Gaoyang Liang, Annette R Atkins, Galina Erikson, Huaiyu Sun, Jill Meisenhelder, Elena Terenziani, Gyunghwi Woo, Linjing Fang, Thom P Santisakultarm, Uri Manor, Rui
代谢
信号转导
肿瘤
胰腺癌
WB
STAT3
发表日期：2019
文献求助 收藏